Articles On EMvision Medical Devices (ASX:EMV)

ASX edges up just 10.8 points or 0.13% Gold holds steady with minor lift overnight as iron ore dips Broad losses in energy as analysts predict supply glut over next 24 months   Info tech fuels fourth day of gains Four sessions of tech-dri...

Stockhead’s Tylah Tully looks at developments from EMvision Medical Devices (ASX:EMV), as the company’s First Responder brain scanner device takes to the skies for testing with the Royal Flying Doctor Service. A feasibility and usability st...

EMVision achieves key milestones in 2025, in development of portable brain-scanning technology Pivotal trial for its first device, the emu, underway – with additional trials in the pipeline or already recruiting Recent $14 million funding...

ASX 200 closes 0.19% higher after choppy session Strength in mining and energy stocks offset pullback across six sectors, with big four banks among hardest hit In boost for healthcare sector, Biotech Nexsen makes strong debut to close 43%...

EMVision to evaluate use of emu brain scanner in regional settings through $3 million CRC-P grant Company to lead a collaboration with the Australian Stroke Alliance, Titan Pre-hospital Innovation, and South Australian Rural Support Servi...

If you have a high tolerance for risk, then it could be worth checking out the small cap ASX share in this article. That's because analysts at Bell Potter are tipping its shares to rise materially over the next 12 months. Which small cap AS...

ASX falls 81 points or 0.92pc by end of trade Utilities and energy sectors the only resistance Financials hit hardest, undercut by inflation numbers ASX returns to September form The ASX 200 is in a snit once again, pulling sharply back i...

Pre-hospital mobile stroke unit ambulance study launched in Melbourne Study will assess First Responder Brain Scanner product, with usability, workflow integration and data collection objectives Study undertaken in collaboration with Austr...

FDA classifies medical devices based on the type of device and the level of risk it poses Three main FDA clearances for medical devices are 510(k), de novo and pre-market approval  Several ASX companies have recently been granted FDA clear...

EMVision banks $12m to speed up stroke care devices Its portable scanners target the gap CT can’t fill Trials and FDA path put the emu device close to market   When it comes to stroke, every minute counts. The difference between walking o...

ASX heath sector falls 1.09% over past five days, while broader markets down 0.66% for same period Study shows PolyNovo’s NovoSorb BTM accelerates healing of large post-surgical diabetes-related foot wounds  Stockhead to join with IR Depar...

Emvision secures $12 million in a placement, with up to $3 million to come in a share purchase plan Painchek’s Highland Fling reaps trial rewards Visionflex cleans up its balance sheet   Emvision Medical Devices (ASX:EMV) has replenished...

ASX recovers from 0.7pc plunge to lose just 0.13pc Gains in energy offset larger losses in gold and healthcare IEL and GYG power consumer discretionary higher ASX makes staged recovery Things weren’t looking great on the ASX 200 this mor...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets – which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the H...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

ASX slides 0.41pc as full year results disappoint Gold, Small Ords, Tech index enjoy late interest-rate-related rally Consumer staples and Coles soften blow   Coles results plus late gold rally soothes market The ASX spent the vast majori...

Leading US stroke centre UCLA Health scheduled for site activation in EMVision’s pivotal trial of emu brain scanner for stroke UCLA Health final site to be activated in trial, joining three US and two Australian comprehensive stroke centr...

Premier US stroke research hub UCLA Health will act as the site for a validation trial and continuous innovation study of EMVision Medical Devices’ (ASX: EMV) new emu brain scanner. The trial site will be led by principal investigator Dr Ma...

Fraser Palamara chats with EMVision Medical Devices (ASX:EMV) CEO and managing director Scott Kirkland to discuss how the company is working to transform stroke care with its portable brain scanning technology. Kirkland explains the urgent...

  In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several compa...

ASX closes out week-long rally on new record high of 8938 points Market set a new intraday high every day this week Broad sector strength, led by financials and materials   From strength to strength The ASX’s trade performance this week h...

Eye drug developer Opthea’s cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today’s sector gains after a US deal with a mystery party    The...

EMVision receives ethics approval for two studies that will advance prototype First Responder toward commercial production Studies designed to demonstrate First Responder brain scanner can fit into emergency workflows and collect valuable...

EchoSolv enters Mayo’s gauntlet for FDA nod Echo’s AI flags heart failure before it hits the fan Other ASX stocks that have trialled with Mayo   On July 1, Echo IQ released an announcement that made cardiologists sit a little straighter....

ASX health up 1.6% over five days as Morgans’ Scott Power says the mood is positive for start of FY26 Wound management house Tetratherix make its ASX debut and breaks an IPO drought for sector ProMedicus surges past $300 for first time fol...

As today’s Medadvisor deal attests, underperforming biotech assets are getting a bite or two Next Science shares continue to rally, but the company is still valued at less than Demant’s offer price for most of its assets Neurizon enters a...

Five of the six pivotal trial sites for EMVision’s emu device for stroke diagnosis now actively enrolling and scanning patients A luminary sixth pivotal trial site preparation is also in progress Approval received to start continuous inno...

ASX heath sector falls 1.1% over past five days The US FDA approves CSL’s Andembry to prevent attacks of hereditary angioedema Clever Culture systems records its second consecutive quarter of positive cashflow operations Healthcare and li...

Highlights: ASX health sector eased, diverging from the broader ASX 200 gains during the week EMVision expanded its pivotal trial and welcomed Ramsay Health Care CEO to the board Dimerix launched clinical activities in Japan...

ASX health stocks dipped 0.82% over the past five days while the broader market has risen 1.26% EMVision appoints Ramsay Health Care CEO to board and expands sites of pivotal trial First Japan site opens for Dimerix’s phase III clinical tr...

Highlights ASX 200 ended marginally lower as miners posted gains but healthcare and finance sectors fell Lithium miners advanced strongly following developments in US policy IDP Education saw notable declines following earni...

Despite a strong start, the ASX has paired back gains to finish down 2.9 points or 0.03pc Weakness came from the Health Care sector and gold stocks Info Tech sector rides semiconductor fever higher, up 0.71pc Despite a strong start to the...

Ramsay Health Care Australia CEO Carmel Monaghan joins board of EMVision Medical Devices Monaghan has worked across hospital, corporate and global positions at Ramsay for almost three decades Appointment comes as EMVision progresses pivot...

Highlights ASX 200 marked a new short-term high, driven by gains in gold and banking sectors Key miners including EPM and NC1 announced significant exploration updates Broader market sentiment remained positive across most s...

ASX adds 52 points, hitting a new 50-day high at 8,466.70 points Broad strength with 9 of 11 sectors on the up Gold and finance stocks outperform The ASX was on a roll today, climbing swiftly in the first hour of trade and maintaining mom...

Stockhead’s Tylah Tully looks at the latest from EMvision Medical Devices (ASX:EMV), who have increased the sites for its pivotal trial for the emu bedside brain scanner, a device designed to rapidly diagnose stroke. Watch the video for mor...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

ASX health stocks up 0.57% over past week, while the broader market is up 0.35%  Wave of capital raisings as ASX-listed healthcare firms seek to strengthen their balance sheets Monash IVF’s woes continue with company downgrading FY25 blami...

Nanosonics scores FDA De Novo approval in March EMVision is also targeting De Novo for its brain scanner The company’s big potential in the US   When Nanosonics (ASX:NAN) landed FDA De Novo clearance for its CORIS system back in March, th...

Highlights Energy, healthcare and telecommunications sectors drove market advances following a policy rate decision Key gainer Adriatic Metals (ADT) saw takeover talks spark share momentum Regulatory and sales setbacks weigh...

The ASX 200 closed up 0.52% at 8,386 points. Energy was the best performing sector, up1%, followed by Health Care, up 0.95%, and Telecommunication, up 0.88%. Industrials was the worst performer, down 0.52%. In the Green Adriatic...

EMVision Medical Devices advances its AI-driven stroke diagnostics Promising new data shows enhanced performance of ‘ischemia or not’ algorithm Data being presented at 11th European Stroke Organisation Conference   Special Report: EMVisi...

EMVision (ASX:EMV), seeking to disrupt the brain scanner tech space, has sent off a second ‘Emu‘ bedside scanner to a US-based Mayo Clinic site for testing. Shortly to be put to the test in the Jacksonville, Florida Mayo facility; so too...

ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir  HealthIn...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

EMVision starts pivotal validation trial for emu bedside brain scanner to diagnose stroke The first Australian site is the Royal Melbourne Hospital The first US site is the University of Texas Health Science Center at Houston (UTHealth) Me...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on April 2 Event to highlight some of ASX’s leading up-and-coming health and life sciences companies EMVision, Microba Life Sciences, Orthocell, Lumos Diagnosti...

Highlights ASX 200 sees movement amid global trade shifts and domestic fiscal debates. Corporate governance and renewable energy projects remain key market influences. Mining sector advancements and healthcare innovations sh...

What had been shaping into a solid little Week 13 for the ASX 200 has been pipped at the post heading into Thursday as Australian shares look to follow the global downturn sparked by Trump’s tariffs campaign resurfacing State-side. Liste...